2025 · 2nd Quarter (Apr 1 - June 30)

ARDELYX, INC.

Filed by ARDELYX, INC..

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 18, 2025
Income: Not reported
Expenses: $540,000.00
Registrant: ARDELYX, INC.
Client: ARDELYX, INC.
Filing UUID: f1530e77-e7c3-4533-a24e-1dfb719afff5
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

H.R.5074, S.4510, Kidney Patient Act, Kidney Health Equity. Access to Innovative Kidney Treatments.

Literal federal measure citations: H.R.5074, S.4510

MMM · Medicare/Medicaid

Medicaid rebate, most favored nation drug pricing. Increase Access to Innovation for People with Kidney Failure. Support Medicare Part D access to phosphorus-lowering medications.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.